FRANKLIN, Tenn. / Oct 23, 2024 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) (the “Company”) today announced financial and operating results for the three and nine months ended September 30, 2024.
The following highlights the financial and operating results for the three months ended September 30, 2024.
Commenting on the results, Tim L. Hingtgen, chief executive officer of Community Health Systems, Inc., said, “Our teams continued to execute well in a number of areas, advancing key priorities related to volume growth, operational improvements and patient outcome success. I especially want to express gratitude for the extraordinary efforts made across many of our health systems to ensure the safety of our patients during back-to-back hurricanes that affected many of our communities.”
Three Months Ended September 30, 2024
Net operating revenues for the three months ended September 30, 2024, totaled $3.090 billion, a 0.1 percent increase compared to $3.086 billion for the same period in 2023. On a same-store basis, net operating revenues increased 5.1 percent for the three months ended September 30, 2024, compared to the same period in 2023. Net operating revenues for the three months ended September 30, 2024, reflect a 4.1 percent decrease in admissions and a 3.7 percent decrease in adjusted admissions, compared to the same period in 2023. On a same-store basis, admissions increased 2.4 percent and adjusted admissions increased 2.6 percent for the three months ended September 30, 2024, compared to the same period in 2023.
Net loss attributable to Community Health Systems, Inc. stockholders was $(391) million, or $(2.95) per share (diluted), for the three months ended September 30, 2024, compared to $(91) million, or $(0.69) per share (diluted), for the same period in 2023. Excluding the adjusting items as presented in the table in footnote (e) on page 15, net loss attributable to Community Health Systems, Inc. stockholders was $(0.30) per share (diluted) for the three months ended September 30, 2024, compared to $(0.33) per share (diluted) for the same period in 2023.
Adjusted EBITDA for the three months ended September 30, 2024, was $347 million compared to $360 million for the same period in 2023.
The increase in net loss attributable to Community Health Systems, Inc. stockholders for the three months ended September 30, 2024, compared to the same period in 2023, was driven by the change in estimate to increase the professional liability claims accrual and period-over-period changes in impairment and (gain) loss on the sale of businesses, partially offset by having a benefit from income taxes in the current period compared to a provision for income taxes in the prior period. In addition, the increase in net loss attributable to Community Health Systems, Inc. stockholders and the decrease in Adjusted EBITDA for the three months ended September 30, 2024, compared to the same period in 2023, was driven by increased expense for salaries and benefits, increased costs for outsourced medical specialists, losses resulting from Hurricane Helene and increased patient claim denials, partially offset by higher same-store volumes, increased reimbursement rates, a higher net benefit from supplemental reimbursement programs, reduced expense for contract labor and reductions in supplies expense.
Nine Months Ended September 30, 2024
Net operating revenues for the nine months ended September 30, 2024, totaled $9.369 billion, a 0.7 percent increase compared to $9.308 billion for the same period in 2023. On a same-store basis, net operating revenues increased 5.2 percent for the nine months ended September 30, 2024, compared to the same period in 2023. Net operating revenues for the nine months ended September 30, 2024, reflect a 3.1 percent decrease in admissions and a 3.4 percent decrease in adjusted admissions, compared to the same period in 2023. On a same-store basis, admissions increased 3.0 percent and adjusted admissions increased 2.5 percent for the nine months ended September 30, 2024, compared to the same period in 2023.
Net loss attributable to Community Health Systems, Inc. stockholders was $(446) million, or $(3.38) per share (diluted), for the nine months ended September 30, 2024, compared to $(180) million, or $(1.38) per share (diluted), for the same period in 2023. Excluding the adjusting items as presented in the table in footnote (e) on page 15, net loss attributable to Community Health Systems, Inc. stockholders was $(0.61) per share (diluted) for the nine months ended September 30, 2024, compared to $(0.98) per share (diluted) for the same period in 2023.
Adjusted EBITDA for the nine months ended September 30, 2024, was $1.112 billion compared to $1.068 billion for the same period in 2023.
The increase in net loss attributable to Community Health Systems, Inc. stockholders for the nine months ended September 30, 2024, compared to the same period in 2023, is primarily attributable to period-over-period changes in impairment and (gain) loss on the sale of businesses and a change in estimate to increase the professional liability claims accrual, partially offset by a gain from early extinguishment of debt, having a benefit from income taxes in the current period compared to a provision for income taxes in the prior period and the factors that contributed to the increase in Adjusted EBITDA as noted below. In addition, the increase in Adjusted EBITDA for the nine months ended September 30, 2024, compared to the same period in 2023, was driven by higher same-store volumes, increased reimbursement rates, favorable changes in payor mix, a higher net benefit from supplemental reimbursement programs, reduced expense for contract labor and reductions in supplies expense, partially offset by lower acuity and increased patient claim denials.
Financing Activity
During the three months ended September 30, 2024, the Company extinguished approximately $143 million principal value of its 5⅝% Senior Secured Notes due 2027 through open market repurchases utilizing cash on hand.
Other
During 2024, through the date of this press release, the Company has completed two hospital divestitures including one on August 1, 2024 and the other on October 1, 2024.
Certain of the Company’s facilities in Florida, Georgia and Tennessee have experienced an interruption in their business and incurred additional costs as a direct result of Hurricane Helene, which made landfall in late September 2024, and Hurricane Milton, which made landfall in early October 2024. Hurricane Helene resulted in an estimated loss of operating revenues together with incremental expenses directly related to hurricane response efforts of approximately $7 million on a pre-tax basis during the three months ended September 30, 2024. No insurance proceeds related to Hurricane Helene were received or recognized during the three months ended September 30, 2024. Further, taking into account the timing of these events, it is expected that additional net operating revenues will be lost and incremental operating expenses will be incurred for remediation and restoration efforts in the fourth quarter of 2024 and one or more future periods. Insurance proceeds, which are expected to cover substantially all of the Company’s costs related to these events, are expected to be received in one or more future periods.
Financial and statistical data presented in this press release includes the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closure. Same-store operating results and statistical information include operating results of businesses operated in the comparable current year and prior year periods and exclude businesses divested in 2024 and 2023.
Information About Non-GAAP Financial Measures
This press release presents Adjusted EBITDA, a non-GAAP financial measure, which is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, expense related to the Business Transformation Costs (as defined in footnote (c) to the Financial Highlights, Financial Statements and Selected Operating Data below), expense related to government and other legal matters and related costs, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations as well as a change in estimate to increase such accrual recorded during the third quarter of 2024 as further described in footnote (c) to the Financial Highlights, Financial Statements and Selected Operating Data below, and the gain on sale by HealthTrust Purchasing Group, L.P. (“HealthTrust”) of a majority interest in CoreTrust Holdings, LLC (“CoreTrust”) completed during the fourth quarter of 2022. For information regarding why the Company believes Adjusted EBITDA provides useful information to investors, and for a reconciliation of Adjusted EBITDA to net loss attributable to Community Health Systems, Inc. stockholders, see footnote (c) to the Financial Highlights, Financial Statements and Selected Operating Data below.
Additionally, this press release presents adjusted net loss attributable to Community Health Systems, Inc. stockholders per share (diluted), a non-GAAP financial measure, to reflect the impact on net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) from the selected items used in the calculation of Adjusted EBITDA. For information regarding why the Company believes this non-GAAP financial measure provides useful information to investors, and for a reconciliation of this non-GAAP financial measure to net loss attributable to Community Health Systems, Inc. stockholders per share (diluted), see footnote (e) to the Financial Highlights, Financial Statements and Selected Operating Data below.
The non-GAAP financial measures set forth above are not measurements of financial performance under U.S. GAAP, and should not be considered in isolation or as a substitute for any financial measure calculated in accordance with U.S. GAAP. Additionally, the calculation of these non-GAAP financial measures may not be comparable to similarly titled measures disclosed by other companies.
Included on pages 16, 17, 18, 19 and 20 of this press release are tables setting forth the Company’s 2024 updated annual earnings guidance. The 2024 guidance is based on the Company’s historical operating performance, current trends and other assumptions the Company believes are reasonable at this time as more specifically discussed below.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 39 distinct markets across 15 states. As of October 23, 2024, the Company’s subsidiaries own or lease 69 affiliated hospitals with more than 11,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers.
The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
Community Health Systems, Inc. will hold a conference call on Thursday, October 24, 2024 at 10:00 a.m. Central, 11:00 a.m. Eastern, to review financial and operating results for the third quarter ended September 30, 2024. Investors will have the opportunity to listen to a live internet broadcast of the conference call by clicking on the Investor Relations link of the Company’s website at www.chs.net. For those who cannot listen to the live broadcast, a replay will be available shortly after the call and will continue to be available for approximately 30 days. Copies of this press release and conference call slide show, as well as the Company’s Current Report on Form 8-K (including this press release), will be available on the Company’s website at www.chs.net.
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | ||||||||||||||||||||
Financial Highlights (a)(b) | ||||||||||||||||||||
(In millions, except per share amounts) | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
| Three Months Ended |
|
|
| Nine Months Ended |
| ||||||||||||||
| September 30, |
|
|
| September 30, |
| ||||||||||||||
| 2024 |
|
| 2023 |
|
|
| 2024 |
|
| 2023 |
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net operating revenues | $ |
| 3,090 |
|
| $ |
| 3,086 |
|
|
| $ |
| 9,369 |
|
| $ |
| 9,308 |
|
Net loss (f) |
|
| (355 | ) |
|
|
| (52 | ) |
|
|
|
| (334 | ) |
|
|
| (70 | ) |
Net loss attributable to Community Health Systems, Inc. stockholders |
|
| (391 | ) |
|
|
| (91 | ) |
|
|
|
| (446 | ) |
|
|
| (180 | ) |
Adjusted EBITDA (c) |
|
| 347 |
|
|
|
| 360 |
|
|
|
|
| 1,112 |
|
|
|
| 1,068 |
|
Net cash provided by operating activities |
|
| 67 |
|
|
|
| 29 |
|
|
|
|
| 264 |
|
|
|
| 120 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Loss per share attributable to Community Health Systems, Inc. stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic (f) | $ |
| (2.95 | ) |
| $ |
| (0.69 | ) |
|
| $ |
| (3.38 | ) |
| $ |
| (1.38 | ) |
Diluted (e), (f) |
|
| (2.95 | ) |
|
|
| (0.69 | ) |
|
|
|
| (3.38 | ) |
|
|
| (1.38 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Weighted-average number of shares outstanding (d): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
|
| 132 |
|
|
|
| 131 |
|
|
|
|
| 132 |
|
|
|
| 130 |
|
Diluted |
|
| 132 |
|
|
|
| 131 |
|
|
|
|
| 132 |
|
|
|
| 130 |
|
__________ | ||||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | |||||||||||||||||||
Condensed Consolidated Statements of Loss (a)(b) | |||||||||||||||||||
(In millions, except per share amounts) | |||||||||||||||||||
(Unaudited) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended September 30, | ||||||||||||||||||
| 2024 |
| 2023 | ||||||||||||||||
|
|
|
|
| % of Net |
|
|
|
|
| % of Net | ||||||||
|
|
|
|
| Operating |
|
|
|
|
| Operating | ||||||||
| Amount |
|
| Revenues |
| Amount |
|
| Revenues | ||||||||||
Net operating revenues | $ |
| 3,090 |
|
|
| 100.0 |
| % |
| $ |
| 3,086 |
|
|
| 100.0 |
| % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Salaries and benefits |
|
| 1,359 |
|
|
| 44.0 |
| % |
|
|
| 1,338 |
|
|
| 43.4 |
| % |
Supplies |
|
| 469 |
|
|
| 15.2 |
| % |
|
|
| 489 |
|
|
| 15.8 |
| % |
Other operating expenses |
|
| 1,010 |
|
|
| 32.6 |
| % |
|
|
| 853 |
|
|
| 27.7 |
| % |
Lease cost and rent |
|
| 73 |
|
|
| 2.4 |
| % |
|
|
| 79 |
|
|
| 2.6 |
| % |
Depreciation and amortization |
|
| 117 |
|
|
| 3.8 |
| % |
|
|
| 128 |
|
|
| 4.1 |
| % |
Impairment and (gain) loss on sale of businesses, net (f) |
|
| 267 |
|
|
| 8.6 |
| % |
|
|
| 26 |
|
|
| 0.8 |
| % |
Total operating expenses |
|
| 3,295 |
|
|
| 106.6 |
| % |
|
|
| 2,913 |
|
|
| 94.4 |
| % |
(Loss) income from operations (f) |
|
| (205 | ) |
|
| (6.6 | ) | % |
|
|
| 173 |
|
|
| 5.6 |
| % |
Interest expense, net |
|
| 216 |
|
|
| 7.1 |
| % |
|
|
| 208 |
|
|
| 6.8 |
| % |
Equity in earnings of unconsolidated affiliates |
|
| (2 | ) |
|
| (0.1 | ) | % |
|
|
| (2 | ) |
|
| (0.1 | ) | % |
Loss before income taxes |
|
| (419 | ) |
|
| (13.6 | ) | % |
|
|
| (33 | ) |
|
| (1.1 | ) | % |
(Benefit from) provision for income taxes |
|
| (64 | ) |
|
| (2.1 | ) | % |
|
|
| 19 |
|
|
| 0.6 |
| % |
Net loss (f) |
|
| (355 | ) |
|
| (11.5 | ) | % |
|
|
| (52 | ) |
|
| (1.7 | ) | % |
Less: Net income attributable to noncontrolling interests |
|
| 36 |
|
|
| 1.2 |
| % |
|
|
| 39 |
|
|
| 1.2 |
| % |
Net loss attributable to Community Health Systems, Inc. stockholders | $ |
| (391 | ) |
|
| (12.7 | ) | % |
| $ |
| (91 | ) |
|
| (2.9 | ) | % |
Loss per share attributable to Community Health Systems, Inc. stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic (f) | $ |
| (2.95 | ) |
|
|
|
|
| $ |
| (0.69 | ) |
|
|
|
| ||
Diluted (e), (f) | $ |
| (2.95 | ) |
|
|
|
|
| $ |
| (0.69 | ) |
|
|
|
| ||
Weighted-average number of shares outstanding (d): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
|
| 132 |
|
|
|
|
|
|
|
| 131 |
|
|
|
|
| ||
Diluted |
|
| 132 |
|
|
|
|
|
|
|
| 131 |
|
|
|
|
| ||
__________ | |||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | |||||||||||||||||||
Condensed Consolidated Statements of Loss (a)(b) | |||||||||||||||||||
(In millions, except per share amounts) | |||||||||||||||||||
(Unaudited) | |||||||||||||||||||
| Nine Months Ended September 30, | ||||||||||||||||||
| 2024 |
| 2023 | ||||||||||||||||
|
|
|
|
| % of Net |
|
|
|
|
| % of Net | ||||||||
|
|
|
|
| Operating |
|
|
|
|
| Operating | ||||||||
| Amount |
|
| Revenues |
| Amount |
|
| Revenues | ||||||||||
Net operating revenues | $ |
| 9,369 |
|
|
| 100.0 |
| % |
| $ |
| 9,308 |
|
|
| 100.0 |
| % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Salaries and benefits |
|
| 4,054 |
|
|
| 43.3 |
| % |
|
|
| 4,040 |
|
|
| 43.4 |
| % |
Supplies |
|
| 1,439 |
|
|
| 15.4 |
| % |
|
|
| 1,499 |
|
|
| 16.1 |
| % |
Other operating expenses |
|
| 2,737 |
|
|
| 29.2 |
| % |
|
|
| 2,524 |
|
|
| 27.1 |
| % |
Lease cost and rent |
|
| 224 |
|
|
| 2.4 |
| % |
|
|
| 240 |
|
|
| 2.6 |
| % |
Depreciation and amortization |
|
| 357 |
|
|
| 3.8 |
| % |
|
|
| 384 |
|
|
| 4.1 |
| % |
Impairment and (gain) loss on sale of businesses, net (f) |
|
| 294 |
|
|
| 3.1 |
| % |
|
|
| (9 | ) |
|
| (0.1 | ) | % |
Total operating expenses |
|
| 9,105 |
|
|
| 97.2 |
| % |
|
|
| 8,678 |
|
|
| 93.2 |
| % |
Income from operations (f) |
|
| 264 |
|
|
| 2.8 |
| % |
|
|
| 630 |
|
|
| 6.8 |
| % |
Interest expense, net |
|
| 643 |
|
|
| 6.9 |
| % |
|
|
| 621 |
|
|
| 6.7 |
| % |
Gain from early extinguishment of debt |
|
| (25 | ) |
|
| (0.3 | ) | % |
|
|
| - |
|
|
| - |
| % |
Equity in earnings of unconsolidated affiliates |
|
| (7 | ) |
|
| (0.1 | ) | % |
|
|
| (5 | ) |
|
| (0.1 | ) | % |
(Loss) income before income taxes |
|
| (347 | ) |
|
| (3.7 | ) | % |
|
|
| 14 |
|
|
| 0.2 |
| % |
(Benefit from) provision for income taxes |
|
| (13 | ) |
|
| (0.1 | ) | % |
|
|
| 84 |
|
|
| 1.0 |
| % |
Net loss (f) |
|
| (334 | ) |
|
| (3.6 | ) | % |
|
|
| (70 | ) |
|
| (0.8 | ) | % |
Less: Net income attributable to noncontrolling interests |
|
| 112 |
|
|
| 1.2 |
| % |
|
|
| 110 |
|
|
| 1.1 |
| % |
Net loss attributable to Community Health Systems, Inc. stockholders | $ |
| (446 | ) |
|
| (4.8 | ) | % |
| $ |
| (180 | ) |
|
| (1.9 | ) | % |
Loss per share attributable to Community Health Systems, Inc. stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic (f) | $ |
| (3.38 | ) |
|
|
|
|
| $ |
| (1.38 | ) |
|
|
|
| ||
Diluted (e), (f) | $ |
| (3.38 | ) |
|
|
|
|
| $ |
| (1.38 | ) |
|
|
|
| ||
Weighted-average number of shares outstanding (d): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
|
| 132 |
|
|
|
|
|
|
|
| 130 |
|
|
|
|
| ||
Diluted |
|
| 132 |
|
|
|
|
|
|
|
| 130 |
|
|
|
|
| ||
__________ | |||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | |||||||||||||||||||
Condensed Consolidated Statements of Comprehensive Loss | |||||||||||||||||||
(In millions) | |||||||||||||||||||
(Unaudited) | |||||||||||||||||||
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||||||
| September 30, |
|
| September 30, |
| ||||||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||||||
Net loss | $ |
| (355 | ) |
| $ |
| (52 | ) |
| $ |
| (334 | ) |
| $ |
| (70 | ) |
Other comprehensive income (loss), net of income taxes: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net change in fair value of available-for-sale debt securities, net of tax |
|
| 2 |
|
|
|
| (3 | ) |
|
|
| 4 |
|
|
|
| (1 | ) |
Amortization and recognition of unrecognized pension cost components, net of tax |
|
| 2 |
|
|
|
| - |
|
|
|
| 2 |
|
|
|
| - |
|
Other comprehensive income (loss) |
|
| 4 |
|
|
|
| (3 | ) |
|
|
| 6 |
|
|
|
| (1 | ) |
Comprehensive loss |
|
| (351 | ) |
|
|
| (55 | ) |
|
|
| (328 | ) |
|
|
| (71 | ) |
Less: Comprehensive income attributable to noncontrolling interests |
|
| 36 |
|
|
|
| 39 |
|
|
|
| 112 |
|
|
|
| 110 |
|
Comprehensive loss attributable to Community Health Systems, Inc. stockholders | $ |
| (387 | ) |
| $ |
| (94 | ) |
| $ |
| (440 | ) |
| $ |
| (181 | ) |
__________ | |||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES |
| |||||||||||||||||||||||
Selected Operating Data (a) |
| |||||||||||||||||||||||
(Dollars in millions) |
| |||||||||||||||||||||||
(Unaudited) |
| |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
| Three Months Ended September 30, |
| |||||||||||||||||||||
|
| Consolidated | Same-Store |
| ||||||||||||||||||||
|
| 2024 |
|
| 2023 |
|
| % Change |
|
| 2024 |
|
| 2023 |
|
| % Change |
| ||||||
Number of hospitals (at end of period) |
|
| 70 |
|
|
| 76 |
|
|
|
|
|
| 70 |
|
|
| 70 |
|
|
|
| ||
Licensed beds (at end of period) |
|
| 11,517 |
|
|
| 12,494 |
|
|
|
|
|
| 11,517 |
|
|
| 11,544 |
|
|
|
| ||
Beds in service (at end of period) |
|
| 9,889 |
|
|
| 10,621 |
|
|
|
|
|
| 9,889 |
|
|
| 9,917 |
|
|
|
| ||
Admissions |
|
| 104,593 |
|
|
| 109,043 |
|
|
| -4.1 | % |
|
| 103,774 |
|
|
| 101,312 |
|
|
| 2.4 | % |
Adjusted admissions |
|
| 240,701 |
|
|
| 249,988 |
|
|
| -3.7 | % |
|
| 238,812 |
|
|
| 232,799 |
|
|
| 2.6 | % |
Patient days |
|
| 453,053 |
|
|
| 459,838 |
|
|
|
|
|
| 449,574 |
|
|
| 443,819 |
|
|
|
| ||
Average length of stay (days) |
|
| 4.3 |
|
|
| 4.2 |
|
|
|
|
|
| 4.3 |
|
|
| 4.4 |
|
|
|
| ||
Occupancy rate (average beds in service) |
|
| 49.8 | % |
|
| 47.1 | % |
|
|
|
|
| 49.4 | % |
|
| 48.6 | % |
|
|
| ||
Net operating revenues |
| $ | 3,090 |
|
| $ | 3,086 |
|
|
| 0.1 | % |
| $ | 3,073 |
|
| $ | 2,923 |
|
|
| 5.1 | % |
Net inpatient revenues as a % of net operating revenues |
|
| 47.2 | % |
|
| 46.5 | % |
|
|
|
|
| 47.2 | % |
|
| 46.2 | % |
|
|
| ||
Net outpatient revenues as a % of net operating revenues |
|
| 52.8 | % |
|
| 53.5 | % |
|
|
|
|
| 52.8 | % |
|
| 53.8 | % |
|
|
| ||
(Loss) income from operations (f) |
| $ | (205 | ) |
| $ | 173 |
|
|
| -218.5 | % |
|
|
|
|
|
|
|
|
| |||
(Loss) income from operations as a % of net operating revenues |
|
| -6.6 | % |
|
| 5.6 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Depreciation and amortization |
| $ | 117 |
|
| $ | 128 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss attributable to Community Health Systems, Inc. stockholders |
| $ | (391 | ) |
| $ | (91 | ) |
|
| -329.7 | % |
|
|
|
|
|
|
|
|
| |||
Net loss attributable to Community Health Systems, Inc. stockholders as a % of net operating revenues |
|
| -12.7 | % |
|
| -2.9 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted EBITDA (c) |
| $ | 347 |
|
| $ | 360 |
|
|
| -3.6 | % |
|
|
|
|
|
|
|
|
| |||
Adjusted EBITDA as a % of net operating revenues |
|
| 11.2 | % |
|
| 11.7 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net cash provided by operating activities |
| $ | 67 |
|
| $ | 29 |
|
|
| 131.0 | % |
|
|
|
|
|
|
|
|
| |||
__________ | ||||||||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | ||||||||||||||||||||||||
Selected Operating Data (a) | ||||||||||||||||||||||||
(Dollars in millions) | ||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||
|
| Nine Months Ended September 30, |
| |||||||||||||||||||||
|
| Consolidated | Same-Store |
| ||||||||||||||||||||
|
| 2024 |
|
| 2023 |
|
| % Change |
|
| 2024 |
|
| 2023 |
|
| % Change |
| ||||||
Number of hospitals (at end of period) |
|
| 70 |
|
|
| 76 |
|
|
|
|
|
| 70 |
|
|
| 70 |
|
|
|
| ||
Licensed beds (at end of period) |
|
| 11,517 |
|
|
| 12,494 |
|
|
|
|
|
| 11,517 |
|
|
| 11,544 |
|
|
|
| ||
Beds in service (at end of period) |
|
| 9,889 |
|
|
| 10,621 |
|
|
|
|
|
| 9,889 |
|
|
| 9,917 |
|
|
|
| ||
Admissions |
|
| 317,396 |
|
|
| 327,466 |
|
|
| -3.1 | % |
|
| 311,613 |
|
|
| 302,447 |
|
|
| 3.0 | % |
Adjusted admissions |
|
| 719,941 |
|
|
| 745,207 |
|
|
| -3.4 | % |
|
| 707,201 |
|
|
| 689,983 |
|
|
| 2.5 | % |
Patient days |
|
| 1,405,286 |
|
|
| 1,453,905 |
|
|
|
|
|
| 1,378,445 |
|
|
| 1,360,574 |
|
|
|
| ||
Average length of stay (days) |
|
| 4.4 |
|
|
| 4.4 |
|
|
|
|
|
| 4.4 |
|
|
| 4.5 |
|
|
|
| ||
Occupancy rate (average beds in service) |
|
| 51.9 | % |
|
| 50.1 | % |
|
|
|
|
| 50.9 | % |
|
| 50.3 | % |
|
|
| ||
Net operating revenues |
| $ | 9,369 |
|
| $ | 9,308 |
|
|
| 0.7 | % |
| $ | 9,255 |
|
| $ | 8,801 |
|
|
| 5.2 | % |
Net inpatient revenues as a % of net operating revenues |
|
| 47.6 | % |
|
| 46.9 | % |
|
|
|
|
| 47.5 | % |
|
| 46.7 | % |
|
|
| ||
Net outpatient revenues as a % of net operating revenues |
|
| 52.4 | % |
|
| 53.1 | % |
|
|
|
|
| 52.5 | % |
|
| 53.3 | % |
|
|
| ||
Income from operations (f) |
| $ | 264 |
|
| $ | 630 |
|
|
| -58.1 | % |
|
|
|
|
|
|
|
|
| |||
Income from operations as a % of net operating revenues |
|
| 2.8 | % |
|
| 6.8 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Depreciation and amortization |
| $ | 357 |
|
| $ | 384 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss attributable to Community Health Systems, Inc. stockholders |
| $ | (446 | ) |
| $ | (180 | ) |
|
| -147.8 | % |
|
|
|
|
|
|
|
|
| |||
Net loss attributable to Community Health Systems, Inc. stockholders as a % of net operating revenues |
|
| -4.8 | % |
|
| -1.9 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted EBITDA (c) |
| $ | 1,112 |
|
| $ | 1,068 |
|
|
| 4.1 | % |
|
|
|
|
|
|
|
|
| |||
Adjusted EBITDA as a % of net operating revenues |
|
| 11.9 | % |
|
| 11.5 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net cash provided by operating activities |
| $ | 264 |
|
| $ | 120 |
|
|
| 120.0 | % |
|
|
|
|
|
|
|
|
| |||
__________ | ||||||||||||||||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | ||||||||||
Condensed Consolidated Balance Sheets | ||||||||||
(In millions, except share data) | ||||||||||
(Unaudited) | ||||||||||
|
| September 30, 2024 |
|
| December 31, 2023 |
| ||||
ASSETS |
|
|
|
|
|
|
|
| ||
Current assets |
|
|
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ |
| 33 |
|
| $ |
| 38 |
|
Patient accounts receivable |
|
|
| 2,043 |
|
|
|
| 2,231 |
|
Supplies |
|
|
| 311 |
|
|
|
| 328 |
|
Prepaid income taxes |
|
|
| 92 |
|
|
|
| 76 |
|
Prepaid expenses and taxes |
|
|
| 227 |
|
|
|
| 260 |
|
Other current assets |
|
|
| 402 |
|
|
|
| 275 |
|
Total current assets |
|
|
| 3,108 |
|
|
|
| 3,208 |
|
Property and equipment |
|
|
| 9,094 |
|
|
|
| 9,511 |
|
Less accumulated depreciation and amortization |
|
|
| (4,130 | ) |
|
|
| (4,304 | ) |
Property and equipment, net |
|
|
| 4,964 |
|
|
|
| 5,207 |
|
Goodwill |
|
|
| 3,940 |
|
|
|
| 3,958 |
|
Deferred income taxes |
|
|
| 29 |
|
|
|
| 29 |
|
Other assets, net |
|
|
| 1,864 |
|
|
|
| 2,053 |
|
Total assets |
| $ |
| 13,905 |
|
| $ |
| 14,455 |
|
|
|
|
|
|
|
|
|
| ||
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
| ||
Current liabilities |
|
|
|
|
|
|
|
| ||
Current maturities of long-term debt |
| $ |
| 20 |
|
| $ |
| 21 |
|
Current operating lease liabilities |
|
|
| 113 |
|
|
|
| 124 |
|
Accounts payable |
|
|
| 842 |
|
|
|
| 912 |
|
Accrued liabilities: |
|
|
|
|
|
|
|
| ||
Employee compensation |
|
|
| 460 |
|
|
|
| 571 |
|
Accrued interest |
|
|
| 198 |
|
|
|
| 160 |
|
Other |
|
|
| 493 |
|
|
|
| 354 |
|
Total current liabilities |
|
|
| 2,126 |
|
|
|
| 2,142 |
|
Long-term debt (g) |
|
|
| 11,467 |
|
|
|
| 11,466 |
|
Deferred income taxes |
|
|
| 239 |
|
|
|
| 369 |
|
Long-term operating lease liabilities |
|
|
| 528 |
|
|
|
| 563 |
|
Other long-term liabilities |
|
|
| 815 |
|
|
|
| 739 |
|
Total liabilities |
|
|
| 15,175 |
|
|
|
| 15,279 |
|
Redeemable noncontrolling interests in equity of consolidated subsidiaries |
|
|
| 322 |
|
|
|
| 323 |
|
STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
| ||
Community Health Systems, Inc. stockholders’ deficit: |
|
|
|
|
|
|
|
| ||
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued |
|
|
| - |
|
|
|
| - |
|
Common stock, $.01 par value per share, 300,000,000 shares authorized; 138,936,058 shares issued and outstanding at September 30, 2024, and 136,774,911 shares issued and outstanding at December 31, 2023 |
|
|
| 1 |
|
|
|
| 1 |
|
Additional paid-in capital |
|
|
| 2,194 |
|
|
|
| 2,185 |
|
Accumulated other comprehensive loss |
|
|
| (8 | ) |
|
|
| (14 | ) |
Accumulated deficit |
|
|
| (4,010 | ) |
|
|
| (3,564 | ) |
Total Community Health Systems, Inc. stockholders’ deficit |
|
|
| (1,823 | ) |
|
|
| (1,392 | ) |
Noncontrolling interests in equity of consolidated subsidiaries |
|
|
| 231 |
|
|
|
| 245 |
|
Total stockholders’ deficit |
|
|
| (1,592 | ) |
|
|
| (1,147 | ) |
Total liabilities and stockholders’ deficit |
| $ |
| 13,905 |
|
| $ |
| 14,455 |
|
__________ | ||||||||||
For footnotes, see pages 13, 14 and 15. |
COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES | |||||||||
Condensed Consolidated Statements of Cash Flows | |||||||||
(In millions) | |||||||||
(Unaudited) | |||||||||
| Nine Months Ended September 30, |
| |||||||
| 2024 |
|
| 2023 |
| ||||
Cash flows from operating activities |
|
|
|
|
|
|
| ||
Net loss | $ |
| (334 | ) |
| $ |
| (70 | ) |
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
|
|
| ||
Depreciation and amortization |
|
| 357 |
|
|
|
| 384 |
|
Deferred income taxes |
|
| (129 | ) |
|
|
| 22 |
|
Stock-based compensation expense |
|
| 12 |
|
|
|
| 16 |
|
Impairment and (gain) loss on sale of businesses, net (f) |
|
| 294 |
|
|
|
| (9 | ) |
Gain from early extinguishment of debt |
|
| (25 | ) |
|
|
| - |
|
Other non-cash expenses, net |
|
| 142 |
|
|
|
| 132 |
|
Changes in operating assets and liabilities, net of effects of |
|
|
|
|
|
|
| ||
acquisitions and divestitures: |
|
|
|
|
|
|
| ||
Patient accounts receivable |
|
| 126 |
|
|
|
| (119 | ) |
Supplies, prepaid expenses and other current assets |
|
| (48 | ) |
|
|
| (100 | ) |
Accounts payable, accrued liabilities and income taxes |
|
| (119 | ) |
|
|
| (69 | ) |
Other |
|
| (12 | ) |
|
|
| (67 | ) |
Net cash provided by operating activities |
|
| 264 |
|
|
|
| 120 |
|
|
|
|
|
|
|
|
| ||
Cash flows from investing activities |
|
|
|
|
|
|
| ||
Acquisitions of facilities and other related businesses |
|
| (1 | ) |
|
|
| (35 | ) |
Purchases of property and equipment |
|
| (251 | ) |
|
|
| (357 | ) |
Proceeds from disposition of hospitals and other ancillary operations |
|
| 174 |
|
|
|
| 123 |
|
Proceeds from sale of property and equipment |
|
| 5 |
|
|
|
| 27 |
|
Purchases of available-for-sale debt securities and equity securities |
|
| (54 | ) |
|
|
| (126 | ) |
Proceeds from sales of available-for-sale debt securities and equity securities |
|
| 54 |
|
|
|
| 221 |
|
Purchases of investments in unconsolidated affiliates |
|
| (4 | ) |
|
|
| (8 | ) |
Increase in other investments |
|
| (55 | ) |
|
|
| (51 | ) |
Net cash used in investing activities |
|
| (132 | ) |
|
|
| (206 | ) |
|
|
|
|
|
|
|
| ||
Cash flows from financing activities |
|
|
|
|
|
|
| ||
Repurchase of restricted stock shares for payroll tax withholding requirements |
|
| (2 | ) |
|
|
| (4 | ) |
Deferred financing costs and other debt-related costs |
|
| (8 | ) |
|
|
| - |
|
Proceeds from noncontrolling investors in joint ventures |
|
| 1 |
|
|
|
| 4 |
|
Redemption of noncontrolling investments in joint ventures |
|
| (3 | ) |
|
|
| (1 | ) |
Distributions to noncontrolling investors in joint ventures |
|
| (121 | ) |
|
|
| (108 | ) |
Other borrowings |
|
| 18 |
|
|
|
| 30 |
|
Issuance of long-term debt |
|
| 1,236 |
|
|
|
| - |
|
Proceeds from ABL Facility |
|
| 2,662 |
|
|
|
| 2,290 |
|
Repayments of long-term indebtedness |
|
| (3,920 | ) |
|
|
| (2,152 | ) |
Net cash (used in) provided by financing activities |
|
| (137 | ) |
|
|
| 59 |
|
|
|
|
|
|
|
|
| ||
Net change in cash and cash equivalents |
|
| (5 | ) |
|
|
| (27 | ) |
Cash and cash equivalents at beginning of period |
|
| 38 |
|
|
|
| 118 |
|
Cash and cash equivalents at end of period | $ |
| 33 |
|
| $ |
| 91 |
|
__________ | |||||||||
For footnotes, see pages 13, 14 and 15. |
Footnotes to Financial Highlights, Financial Statements and Selected Operating Data
(a) | Both financial and statistical results include the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closing. Same-store operating results and statistical information include operating results of businesses operated in the comparable current year and prior year periods and exclude businesses divested in 2024 and 2023. There were no discontinued operations reported for the periods presented. | |
(b) | The following table provides information needed to calculate loss per share, which is adjusted for income attributable to noncontrolling interests (in millions): |
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||||||
| September 30, |
|
| September 30, |
| ||||||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||||||
Net loss attributable to Community Health Systems, Inc. stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss | $ |
| (355 | ) |
| $ |
| (52 | ) |
| $ |
| (334 | ) |
| $ |
| (70 | ) |
Less: Income attributable to noncontrolling interests, net of taxes |
|
| 36 |
|
|
|
| 39 |
|
|
|
| 112 |
|
|
|
| 110 |
|
Net loss attributable to Community Health Systems, Inc. stockholders — basic and diluted | $ |
| (391 | ) |
| $ |
| (91 | ) |
| $ |
| (446 | ) |
| $ |
| (180 | ) |
(c) | EBITDA is a non-GAAP financial measure which consists of net loss attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, expense from third-party consulting costs associated with significant process and systems redesign across multiple functions (the “Business Transformation Costs”) as part of the Company’s previously disclosed multi-year initiative to modernize and consolidate technology platforms and associated processes, expense related to government and other legal matters and related costs, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations as well as a change in estimate to increase such accrual recorded during the third quarter of 2024 as described below, and the gain on sale by HealthTrust of a majority interest in CoreTrust completed during the fourth quarter of 2022. The Company has included an adjustment to Adjusted EBITDA during the three months ended September 30, 2024, for the change in estimate to increase the professional liability claims accrual resulting from emergence in the period of adverse developments, including from social inflationary pressures, which affected the actuarially determined estimate for the resolution of professional liability claims. The Company, with input from its third-party actuary, considered recent increases in the amounts the Company has paid to resolve outstanding professional liability claims arising in prior periods as well as increases in individual claim accruals for unresolved prior period claims, the majority of which increases in amounts and individual claim accruals relate to divested locations. The Company believes that this increase in estimate is not reflective of the Company’s underlying results of operations and that the exclusion of this item from the calculation of Adjusted EBITDA for the three months ended September 30, 2024, is consistent with the intended purpose of Adjusted EBITDA in assessing the Company’s operational performance and comparing the Company’s operational performance between periods. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company’s hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company’s executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company’s consolidated results of operations and operational performance and in comparing the Company’s results of operations between periods. |
Footnotes to Financial Highlights, Financial Statements and Selected Operating Data (Continued)
The Company believes it is useful to provide investors and other users of the Company’s financial statements this performance measure to align with how management assesses the Company’s results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company’s asset-based loan facility (the “ABL Facility”) and the Company’s existing note indentures, which is a key component in the determination of the Company’s compliance with certain covenants under the ABL Facility and such note indentures (including the Company’s ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). Adjusted EBITDA includes the Adjusted EBITDA attributable to hospitals that were divested during the course of such year, but in each case solely to the extent relating to the period prior to the consummation of the applicable divestiture.
Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures disclosed by other companies.
The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):
| Three Months Ended |
|
|
|
| Nine Months Ended |
| ||||||||||||||
| September 30, |
|
|
|
| September 30, |
| ||||||||||||||
| 2024 |
|
| 2023 |
|
|
|
| 2024 |
|
| 2023 |
| ||||||||
Net loss attributable to Community Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Systems, Inc. stockholders | $ |
| (391 | ) |
| $ |
| (91 | ) |
|
|
| $ |
| (446 | ) |
| $ |
| (180 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
(Benefit from) provision for income taxes |
|
| (64 | ) |
|
|
| 19 |
|
|
|
|
|
| (13 | ) |
|
|
| 84 |
|
Depreciation and amortization |
|
| 117 |
|
|
|
| 128 |
|
|
|
|
|
| 357 |
|
|
|
| 384 |
|
Net income attributable to noncontrolling interests |
|
| 36 |
|
|
|
| 39 |
|
|
|
|
|
| 112 |
|
|
|
| 110 |
|
Interest expense, net |
|
| 216 |
|
|
|
| 208 |
|
|
|
|
|
| 643 |
|
|
|
| 621 |
|
Gain from early extinguishment of debt |
|
| - |
|
|
|
| - |
|
|
|
|
|
| (25 | ) |
|
|
| - |
|
Impairment and (gain) loss on sale of businesses, net |
|
| 267 |
|
|
|
| 26 |
|
|
|
|
|
| 294 |
|
|
|
| (9 | ) |
Expense from government and other legal matters and related costs |
|
| - |
|
|
|
| 24 |
|
|
|
|
|
| - |
|
|
|
| 33 |
|
Expense from business transformation costs |
|
| 17 |
|
|
|
| 6 |
|
|
|
|
|
| 41 |
|
|
|
| 13 |
|
Expense related to employee termination benefits and other restructuring charges |
|
| - |
|
|
|
| 1 |
|
|
|
|
|
| - |
|
|
|
| 12 |
|
Change in estimate for professional claims liability |
|
| 149 |
|
|
|
| - |
|
|
|
|
|
| 149 |
|
|
|
| - |
|
Adjusted EBITDA | $ |
| 347 |
|
| $ |
| 360 |
|
|
|
| $ |
| 1,112 |
|
| $ |
| 1,068 |
|
(d) | The following table sets forth components reconciling the basic weighted-average number of shares to the diluted weighted-average number of shares (in millions): |
| Three Months Ended |
|
|
| Nine Months Ended |
| ||||||||||
| September 30, |
|
|
| September 30, |
| ||||||||||
| 2024 |
|
| 2023 |
|
|
| 2024 |
|
| 2023 |
| ||||
Weighted-average number of shares outstanding - basic |
| 132 |
|
|
| 131 |
|
|
|
| 132 |
|
|
| 130 |
|
Add effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Stock awards and options |
| - |
|
|
| - |
|
|
|
| - |
|
|
| - |
|
Weighted-average number of shares outstanding - diluted |
| 132 |
|
|
| 131 |
|
|
|
| 132 |
|
|
| 130 |
|
Footnotes to Financial Highlights, Financial Statements and Selected Operating Data (Continued)
The Company generated a net loss attributable to Community Health Systems, Inc. stockholders for the three and nine months ended September 30, 2024 and 2023, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated net income, the effect of stock awards and options on the diluted shares calculation would have been an increase of 1,883,693 shares and 224,178 shares during the three months ended September 30, 2024 and 2023, respectively, and 1,064,103 shares and 298,184 shares during the nine months ended September 30, 2024 and 2023, respectively.
(e) | The following supplemental table reconciles net loss attributable to Community Health Systems, Inc. stockholders, as reported, on a per share (diluted) basis, to net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) with the adjustments described herein (total per share amounts may not add due to rounding). The Company believes that the presentation of non-GAAP adjusted net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) presents useful information to investors by highlighting the impact on net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) of selected items used in calculating Adjusted EBITDA which may not reflect the Company’s underlying operating performance and assisting in comparing the Company’s results of operations between periods. |
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||
| September 30, |
|
| September 30, |
| ||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
Net loss per share (diluted), as reported | $ | (2.95 | ) |
| $ | (0.69 | ) |
| $ | (3.38 | ) |
| $ | (1.38 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
| ||||
Gain from early extinguishment of debt |
| - |
|
|
| - |
|
|
| (0.20 | ) |
|
| - |
|
Impairment and (gain) loss on sale of businesses, net |
| 1.68 |
|
|
| 0.18 |
|
|
| 1.85 |
|
|
| 0.05 |
|
Expense from government and other legal matters and related costs |
| - |
|
|
| 0.14 |
|
|
| - |
|
|
| 0.20 |
|
Expense from business transformation costs |
| 0.10 |
|
|
| 0.04 |
|
|
| 0.25 |
|
|
| 0.08 |
|
Expense related to employee termination benefits and other restructuring charges |
| - |
|
|
| 0.01 |
|
|
| - |
|
|
| 0.07 |
|
Change in estimate for professional claims liability |
| 0.87 |
|
|
| - |
|
|
| 0.88 |
|
|
| - |
|
Net loss per share (diluted), excluding adjustments | $ | (0.30 | ) |
| $ | (0.33 | ) |
| $ | (0.61 | ) |
| $ | (0.98 | ) |
(f) | Both (loss) income from operations and net loss included a net non-cash impairment expense of $267 million and $26 million for the three months ended September 30, 2024 and 2023, respectively, and a net non-cash impairment expense of $294 million and income of $9 million for the nine months ended September 30, 2024 and 2023, respectively. The impairment expense for 2024 was primarily from impairment expense to reduce the carrying value of several assets that were idled, disposed of or held-for-sale and partially offset by gains on the sale of certain businesses during the periods. The income for 2023 was primarily from gains on the sale of certain businesses during the periods and also impairment charges to reduce the value of certain long-lived assets at businesses the Company identified for closure, sale or sold. These gains and impairment charges do not have an impact on the calculation of the Company’s financial covenants under the ABL Facility. | |
(g) | The maximum aggregate principal amount under the ABL Facility is $1.0 billion, subject to borrowing base capacity. At September 30, 2024, the Company had outstanding borrowings of $372 million and approximately $438 million of additional borrowing capacity (after taking into consideration $66 million of outstanding letters of credit) under the ABL Facility. |
Regulation FD Disclosure
Set forth below is selected information concerning the Company’s projected consolidated operating results for the year ending December 31, 2024. These projections update selected guidance provided on July 24, 2024, and are based on the Company’s historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time. This 2024 guidance should be considered in conjunction with the assumptions included herein. See pages 18, 19 and 20 for a list of factors that could affect the future results of the Company or the healthcare industry generally. The following is provided as guidance to analysts and investors:
| 2024 Projection Range |
| ||||||||||
Net operating revenues (in millions) | $ |
| 12,450 |
|
|
| to |
| $ |
| 12,550 |
|
Adjusted EBITDA (in millions) | $ |
| 1,500 |
|
|
| to |
| $ |
| 1,540 |
|
Net loss per share - diluted | $ |
| (0.60 | ) |
|
| to |
| $ |
| (0.50 | ) |
Weighted-average diluted shares (in millions) |
|
| 132 |
|
|
| to |
|
|
| 133 |
|
The following assumptions were used in developing the 2024 guidance provided above:
Other assumptions used in the above guidance:
A reconciliation of the Company’s projected 2024 Adjusted EBITDA, a forward-looking non-GAAP financial measure, to the Company’s projected net loss attributable to Community Health Systems, Inc. stockholders, the most directly comparable GAAP financial measure, is shown below (in millions):
| Year Ending |
|
| |||||||
| December 31, 2024 |
|
| |||||||
| Low |
|
| High |
|
| ||||
Net loss attributable to Community Health Systems, Inc. stockholders (1) | $ |
| (79 | ) |
| $ |
| (66 | ) |
|
Adjustments: |
|
|
|
|
|
|
|
| ||
Depreciation and amortization |
|
| 465 |
|
|
|
| 480 |
|
|
Interest expense, net |
|
| 860 |
|
|
|
| 850 |
|
|
Provision for income taxes |
|
| 104 |
|
|
|
| 116 |
|
|
Net income attributable to noncontrolling interests |
|
| 150 |
|
|
|
| 160 |
|
|
Adjusted EBITDA (1) | $ |
| 1,500 |
|
| $ |
| 1,540 |
|
|
(1) | The Company does not include in this reconciliation the impact of certain items not included in the Company’s forecast set forth above that would be included in a reconciliation of historical net loss attributable to Community Health Systems, Inc. stockholders to Adjusted EBITDA such as, but not limited to, losses (gains) from early extinguishment of debt, impairment and (gain) loss on sale of businesses and expense from government and other legal matters and related costs, in light of the fact that such items are not determinable, and/or the inherent difficulty in quantifying such projected amounts, on a forward-looking basis. |
| 2024 |
| |||||||
| Guidance |
| |||||||
Total | $ | 350 |
|
| to |
| $ | 400 |
|
| 2024 |
| |||||||
| Guidance |
| |||||||
Total | $ | 400 |
|
| to |
| $ | 500 |
|
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this press release.
These factors include, among other things:
The consolidated operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the projections for calendar year 2024 set forth in this press release are given as of the date hereof based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements (including such guidance), or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Last Trade: | US$4.05 |
Daily Change: | -0.27 -6.25 |
Daily Volume: | 1,702,134 |
Market Cap: | US$562.710M |
September 16, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB